Jade Biosciences (JBIO) Wells Fargo 21st Annual Healthcare Conference summary

Pipeline overview and clinical progress

• Three main assets: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (anti-BAFF-R for autoimmune diseases), and JADE301 (anti-interferon beta for dermatomyositis) are advancing through clinical stages.

• JADE101 showed up to 70% IgA reduction in phase I, with effects sustained for 12 weeks after a single dose.

• Phase II for JADE101 is ongoing, with data expected in 2027; phase III initiation planned for early 2027.

• JADE201 is in phase I for rheumatoid arthritis, with data expected in 2027; future indications will be informed by ongoing trials and competitor data.

• JADE301 is entering phase I, targeting dermatomyositis, with preclinical data to be presented soon and phase I data expected in 2027.

Differentiation and competitive landscape

• JADE101 demonstrates greater potency and longer half-life compared to first-generation and competitor agents, with more consistent and deeper IgA reductions.

• Competitor CLIMB’s molecule shows lower binding affinity and less consistent IgA suppression, with a maximum reduction around 55%.

• PK/PD modeling supports quarterly maintenance dosing for JADE101, maintaining robust IgA reductions.

• Early, deep IgA reduction is linked to greater proteinuria reduction and potential for faster, deeper clinical remission.

• Selective APRIL inhibition is seen as sufficient for eGFR stabilization, with BAFF inhibition adding immunosuppression risk but no added efficacy.

Regulatory and trial design updates

• Phase II for JADE101 is open-label, enrolling up to 30 patients across two dosing intervals; phase III will include both dosing arms to meet regulatory expectations.

• Regulatory consensus is moving toward one-year placebo-controlled trials with proteinuria and eGFR endpoints, without active comparators, due to new standards of care.

• Commercialization strategy is focused on rapid advancement and leveraging robust phase I data to accelerate phase III initiation.